Precision Biosciences Inc

NASDAQ:DTIL   3:59:44 PM EDT
11.50
-0.24 (-2.04%)
Products, Strategic Combinations, Other Pre-Announcement

Lilly And Precision Biosciences Announce Genome Editing Research Collaboration And License Agreement

Published: 11/20/2020 12:42 GMT
Precision BioSciences Inc (DTIL) - Lilly and Precision Biosciences Announce Genome Editing Research Collaboration and License Agreement.
Precision Biosciences Inc - Precision Will Receive $100 Million Cash Upfront and an Equity Investment by Lilly of $35 Million.
Precision Biosciences Inc - Precision Also Eligible to Receive Potential Milestones Up to $420 Million per Product.
Precision Biosciences Inc - Precision Will Lead Pre-clinical Research and Ind-enabling Activities.
Precision Biosciences Inc - Lilly Then Assuming Responsibility for Clinical Development and Commercialization.
Precision Biosciences Inc - Lilly Will Have Right to Select Up to Three Additional Gene Targets for This Collaboration.
Precision Biosciences - Precision Can Co-fund Clinical Development of One Product in Exchange for an Increased Royalty Rate on Co-funded Product Sales.
Precision Biosciences Inc - There Will Be No Change to Lilly's 2020 Non-GAAP Earnings per Share Guidance As a Result of Transaction.